* Cancer medication ex-factory prices, based on price data for 2018; collected from recognized price sources. Countries included in the analysis: United States, United Kingdom, Japan, Canada, Australia, Portugal, France, the Netherlands, Germany, Denmark, Sweden, and Switzerland. Comparison is with U.S. drug prices under Medicare Part D. Information on brand-name cancer medication provided by National Cancer Institute.
Citation formats
Global cancer medication prices in comparison to the U.S., 2018
Although there was variation in the ex-factory price between select cancer medications, in all cases the U.S. price per dose was higher than the average of the ** other countries in this analysis. The four drugs with the highest U.S.-international price differentials were Ibrance, Afinitor, Sprycel and Zytiga. International prices from selected developed countries were compared to U.S. drug prices under Medicare Part D.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
US House of Representatives (Committee on Ways and Means). (September 23, 2019). Price comparison U.S. vs. international per dose for select cancer drugs in 2018* (in U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 23, 2026, from /statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/
US House of Representatives (Committee on Ways and Means). "Price comparison U.S. vs. international per dose for select cancer drugs in 2018* (in U.S. dollars)." Chart. September 23, 2019. ÌÇÐÄÆƽâ°æ. Accessed July 23, 2026. /statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/
US House of Representatives (Committee on Ways and Means). (2019). Price comparison U.S. vs. international per dose for select cancer drugs in 2018* (in U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 23, 2026. /statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/
US House of Representatives (Committee on Ways and Means). "Price Comparison U.S. Vs. International per Dose for Select Cancer Drugs in 2018* (in U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 23 Sep 2019, /statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/
US House of Representatives (Committee on Ways and Means), Price comparison U.S. vs. international per dose for select cancer drugs in 2018* (in U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/ (last visited July 23, 2026)
Price comparison U.S. vs. international per dose for select cancer drugs in 2018* (in U.S. dollars) [Graph], US House of Representatives (Committee on Ways and Means), September 23, 2019. [Online]. Available: /statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/
